Extemporaneous combination therapy with nebivolol/ramipril for the treatment of hypertension: a real-world evidence study in Europe.

Autor:	Desideri G; Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy., Pegoraro V; IQVIA Solutions Italy S.r.l., Milan, Italy., Cipelli R; IQVIA Solutions Italy S.r.l., Milan, Italy., Ripellino C; IQVIA Solutions Italy S.r.l., Milan, Italy., Miroddi M; A. Menarini Farmaceutica Internazionale S.r.l., Florence, Italy., Meto S; A. Menarini Industrie Farmaceutiche Riunite S.r.l., Florence, Italy., Gori M; Menarini Ricerche SpA, Pomezia, Italy., Fabrizzi P; A. Menarini Industrie Farmaceutiche Riunite S.r.l., Florence, Italy.
Jazyk:	angličtina
Zdroj:	Current medical research and opinion [Curr Med Res Opin] 2024 Jul; Vol. 40 (7), pp. 1093-1102. Date of Electronic Publication: 2024 Jun 13.
DOI:	10.1080/03007995.2024.2362276
Abstrakt:	Objectives: To describe the clinical characteristics and treatment adherence in European adult hypertensive patients starting treatment with the extemporaneous combination of nebivolol and ramipril (NR-EXC). Methods: Retrospective database analysis of patients receiving NR-EXC treatment across five European countries (Italy, Germany, France, Poland, Hungary) over a period ranging from 3 to 9 years (until 30 June 2020) according to data availability for the different data sources. Patient demographics, comorbidities, and treatment adherence were evaluated. Results: We identified 592,472 patients starting NR-EXC. Most of them were over 60 years of age, with ramipril most commonly prescribed at 5 mg (from 30.0 to 57.2% of patients across the databases). Notable comorbidities included diabetes (19.2%) and dyslipidemia (18.2%). The study population was also highly subjected to polytherapy with antithrombotics, lipid-lowering agents, and other lowering blood pressure agents as the most co-prescribed medications, as resulted from Italian database. Up to 59% of the patients did not request a cardiologic visit during the study period. Adherence to therapy was low in 56.3% of the patients, and it was high only in 11.1% of them. Conclusions: The combination of nebivolol and ramipril is frequently prescribed in Europe, but adherence to treatment is suboptimal. The transition to a single pill combination could enhance treatment adherence and streamline regimens, potentially leading to significant benefits. Improved adherence not only correlates with better blood pressure control but also reduces the risk of cardiovascular events, underscoring the importance of this development.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu